WELCOME to epgonline.org

Access trusted, independent sources of clinical content for the United Kingdom as well as other regions. Registration is quick and simple, providing you with unlimited access to all content and features.
 

Latest News

Added 23 hours ago Drug news

Data Safety Monitoring Board positive recommendation for RESOLVE-IT Phase III trial of elafibranor to proced for NASH.- Genfit.

GENFIT announced that the Data Safety Monitoring Board (DSMB) issued a new positive recommendation for the continuation of the RESOLVE-IT...

Added 23 hours ago Drug news

FDA Advisory Commmittee recommends baricitinib 2-mg dose to treat Rheumatoid Arthritis but not 4-mg dose.- Eli Lilly + Incyte Corpn.

Eli Lilly and Company and Incyte Corporation announced that the FDA Arthritis Advisory Committee recommended approval of the 2-mg dose...

Added 23 hours ago Drug news

Complete response letter for trastuzumab biosimilar.- Pfizer

Pfizer Inc.announced that it received a Complete Response Letter (CRL) from the FDA in response to the Biologics License Application...

Looking to the horizon - Breakthrough drugs and treatments

Marshall Pearce

Antibody-drug conjugates (ADCs)

Posted 1 year ago

Over the past couple of decades, there have been advances in a class of drugs which for a long time was purely theoretical: antibody-drug conjugates (ADCs). The concept underlying ADCs is elegant – what if it were possible to ‘target’ particular groups of cells with a cytotoxic agent, rather than exposing every cell of the body to it?

Marshall Pearce

Cancer immunotherapies

Posted 1 year ago

It was the winner of the 1908 Nobel prize for medicine, Paul Ehrlich, who is first credited with discussing the concept of a “magic bullet”, able to target specific cells without damaging healthy tissue. With the advent of immunotherapy, as well as antibody-drug conjugates, we are beginning to realise this vision.

Marshall Pearce

How close are we to a disease-modifying treatment for Alzheimer’s?

Posted 4 months ago

Alzheimer’s disease is a snowballing problem, one that is currently without a convincing solution. The progressive decline in cognitive function seen in patients with Alzheimer’s disease is associated strongly with plaques formed of amyloid beta in the brain, creating neurofibrillary tangles and leading to neuronal destruction. While some treatments improve cognition in the short-term, current therapeutic options are unable to modify or slow the disease process.